M&A / Deals Halozyme and Vertex sign deal for Hypercon technology Pharmaceutical Business ReviewVertex has licensed the technology for use in up to three drug targets, as part of the agreement.M&A / DealsRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) Pharmaceutical Business Review Vertex has licensed the technology for use in up to three drug targets, as part of the agreement. M&A / DealsRead full story Post navigation Previous: Gilead continues M&A surge with $3.1B deal for ADC specialist TubulisNext: RoosterBio and MineBio team up to expand MSC solutions access in China Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
